Daiichi Sankyo Kicks Off PIII to Test ADC Follow-Up for Triple-Negative Breast Cancer

Daiichi Sankyo said on June 13 that the first patient has been dosed in a global PIII study investigating its antibody drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) for the first-line treatment of certain patients with advanced triple negative breast cancer...read more